Illumina, Inc.
- Jurisdiction
United States - LEI
SQ95QG8SR5Q56LSNF682 - ISIN
US4523271090 (ILMN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
5
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Read full profile
Fundamentals
- Net revenue
€3.65B - Gross margin
66.5% - EBIT
€1.10B - EBIT margin
30.2% - Net income
€1.07B - Net margin
29.4%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Thomas Kean | May 15, 2025 | $1.00K–$15.00K |
| Thomas Kean | April 18, 2025 | $1.00K–$15.00K |
| Michael Burgess | October 1, 2024 | $15.00K–$50.00K |
| Michael Burgess | September 24, 2024 | $15.00K–$50.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| James Anderson |
|
|
|
Sell |
| Peter Brown |
|
|
|
Buy |
| Cathie Wood |
|
|
|
Buy |